Home Innovation That Matters

Innovation That Matters

SAGE Therapeutics on Fast Track towards CNS Cures

This month's Innovation that Matters (ITM) features Albert J. Robichaud, Ph.D., chief scientific officer of Cambridge, Mass.-based SAGE Therapeutics, which is developing next-generation medicines for the treatment of rare and life-threatening central nervous system (CNS) disorders.  CNS disorders represent 35 percent of the worldwide...

Gene Therapy Offers Potentially New Treatment for beta-Thalassemia Patients

Bluebird Bio Inc., a leading gene therapy biotech company based in Cambridge, Massachusetts, announced on February 2 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to one of its investigational drugs, LentiGlobin® BB305 for the treatment of transfusion-dependent patients...

Inside Perspectives on Immunotherapy: An Interview with Advaxis CEO Daniel O’Connor

Advaxis Immunotherapies, led by President and CEO Daniel O’Connor, is developing a promising and versatile approach to immuno-oncology with its Listeria monocytogenes (Lm) antigen delivery system. Lm Technology™ shows the immune system how to identify and target tumors, weakens tumor defense mechanisms, and triggers...

A Passion for Precision Medicines: How Three Start-ups Are Changing the Paradigm

By Hui Cai, Vice President of Corporate Alliances and Head of Corporate Communications, WuXi AppTec Troy Wilson jokes about time travel being the basis of his next company, and it’s with good reason. A serial entrepreneur, Troy has been remarkably productive over the last several...

Solid as a Rock: Creating a Strong Foundation for Developing First-in-Class Treatments to Fight Aggressive Cancers

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) In the life sciences, disruptive innovation is no longer the exception; it’s the rule. One global R&D executive known for successfully driving innovation is Elaine Sullivan. Sullivan – who has 25 years of...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease...

We are thrilled about WuXi NextCODE's contribution of its artificial intelligence (AI) and sequencing teams to the discovery of a novel mechanism regulating how blood...